NCT00635596已完成1 期
An Open-label, Multi-center Dose Escalation Phase I Study to Investigate the Safety and Tolerability of a Continuous Infusion of the Bispecific T-cell Engager (BiTE) MT110 in Locally Advanced, Recurrent or Metastatic Solid Tumors Which Commonly Express EpCAM and Are Not Amenable to Curative Treatment
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 4
- 主要终点
- Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events [SAEs] and dose-limiting toxicities)
研究概览
简要总结
This phase I dose escalation study is intended to define the safety, tolerability and maximal tolerable dose (MTD) of MT110 in patients with advanced solid tumors.
详细描述
MT110 is a bispecific (anti-EpCAM x anti-CD3) T-cell engager (BiTE) designed to link EpCAM (epithelial cell adhesion molecule) expressing cells and T-cells resulting in T-cell activation and a cytotoxic T-cell response against EpCAM+ cells. In vitro and ex-vivo data indicate that EpCAM+ tumor cell lines are sensitive to MT110 mediated cytotoxicity. Furthermore, data from in-vivo experiments with both MT110 and a mouse surrogate molecule (muS110) have confirmed the activity of these molecules in inhibiting the formation of metastases but also against established tumors. In vitro and ex-vivo data suggest that a prolonged presence of the drug in target tissues may result in significant T-cell recruitment, activation and expansion to/in target tissues, potentially resulting in substantial anti-tumor activity in man.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Locally advanced, recurrent or metastatic solid tumors known to widely express EpCAM and proven histology of the following entities:
- •Adenocarcinoma of the lung
- •Small cell lung cancer (SCLC)
- •Gastric cancer or adenocarcinoma of gastro-esophageal junction
- •Colorectal cancer (CRC)
- •Hormone-refractory prostate cancer (HRPC)
- •Breast cancer
- •Ovarian cancer
- •Patients must not be amenable to curative therapy. Patients should have exhausted or declined standard therapeutic options and previous therapies should have included at least one course of chemotherapy.
- •Non-measurable disease or at least one measurable tumor lesion as per RECIST criteria
- •Age >/= 18 years
- •ECOG performance status </= 2
- •Life expectancy of at least 3 months
- •Must have recovered from the acute reversible effects of previous anti-cancer chemotherapy, endocrine therapy, immunotherapy, radiotherapy or surgery.
- •This generally means at least 4 weeks since major surgery, radical radiotherapy or myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin C).
- •At least 4-5 half-lives (t1/2) must have elapsed since treatment with an investigational agent.
- •At least 4 weeks since any hormonal therapy (except LHRH agonists for patients with HRPC) prior to initiating MT110 treatment.
- •Ability to understand the patient information and informed consent form
- •Signed and dated written informed consent
排除标准
- •Evidence of central nervous system (CNS) metastases on baseline computer tomography (CT) or magnetic resonance imaging (MRI) scan (mandatory for all patients), current or past relevant history of other CNS pathology (except migraine, headache and minor incidental findings in the MRI without any clinical manifestation within the last five years). All minor incidental findings should be discussed with the Sponsor's Medical Monitor).
- •Neutrophil count < 1,500/mm3 (= 1.5 x 10^9/l)
- •Platelet count < 100,000/mm3 (= 100 x 10^9/l)
- •White blood cells (WBC) < 3 x10^9/l
- •Hemoglobin < 9.0 g/dl
- •Abnormal renal or hepatic function as defined below:
- •Alkaline phosphatase (AP)>/= 2.5 x upper limit of normal (ULN) and/or aspartate aminotransferase (AST, SGOT), alanin aminotransferase (ALT, SGPT) >/= 2.0 x ULN or AP, AST and/or ALT >/= 3 x ULN in case of liver metastases; γ-glutamyl transpeptidase (GGT) >/= 5.0 x ULN
- •Total bilirubin >/= 1.5 x ULN
- •Creatinine clearance < 50 ml/min calculated by the Cockroft-Gault formula or MDRD (modification of diet in renal disease)
- •Lipase/amylase > 1.5 x ULN
- •D-dimer >/= 10 x ULN
- •Antithrombin activity < 70%
- •International normalized ratio (INR) > ULN
- •Partial thromboplastin time (PTT) > ULN
- •Oxygen (O2) saturation of < 92% (under room air condition)
- •Any concurrent anti-neoplastic therapy with the exception of radiotherapy for palliation of symptoms after agreement by the Sponsor's Medical Monitor. No radiation is allowed for defined measurable lesions according to RECIST. Patients with HRPC who have received LHRH-agonist therapy for >1 month, should continue agonist therapy.
- •Any concurrent disease, medical or social condition that could affect compliance with the protocol or interpretation of results as judged by the investigator. In particular, patients with the following conditions are not allowed to enter the study:
- •Autoimmune and inflammatory diseases including vasculitis, rheumatoid arthritis, systemic lupus erythematosus (SLE), multiple sclerosis and similar conditions
- •Active infection or known bacteremia
- •Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus
- •Severe dyspnea or pulmonary dysfunction or need for continuous supportive oxygen inhalation
- •Insufficient cardiac function defined as NYHA (New York Heart Association) Grade 3 or 4
- •History of acute or chronic pancreatitis
- •Chronic systemic corticosteroid therapy longer than 2 months or any other immunosuppressive therapies or stem-cell transplantation.
- •Presence of human anti-murine antibodies (HAMA) or known hypersensitivity to immunoglobulins or to other ingredients of the infusion solution.
- •Pregnant, nursing women or women of childbearing potential who are not willing to use effective forms of contraception during participation in the study and at least three months thereafter.
- •Male patients with partners of child-bearing potential who are not willing to use effective contraception during the trial and for at least three months thereafter, unless surgically sterile.
研究组 & 干预措施
I
Experimental
干预措施: MT110 (Biological)
结局指标
主要结局
Overall frequency and intensity of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events [SAEs] and dose-limiting toxicities)
时间窗: one or more treatment cycles
次要结局
- Pharmacokinetics of MT110; T-cell counts, kinetics, and activation status; Serum cytokine concentrations; Immunogenicity; Anti-tumor activity; Other progressive disease (PD) parameters(one or more treatment cycles)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
1 期
Study of SGR-1505 in Mature B-Cell NeoplasmsPrimary Effusion LymphomaMALT LymphomaBurkitt LymphomaALK-Positive Large B-Cell LymphomaMature B-Cell NeoplasmNon Hodgkin LymphomaIRF4 Gene RearrangementEBV-Positive DLBCL, NosPlasmablastic LymphomaHigh-grade B-cell LymphomaPrimary Mediastinal Large B Cell LymphomaPrimary Cutaneous Diffuse Large B-Cell LymphomaSplenic Marginal Zone LymphomaDLBCLHHV8-Positive DLBCL, NosDuodenal-Type Follicular LymphomaMantle Cell LymphomaT-Cell/Histiocyte Rich LymphomaWaldenstrom MacroglobulinemiaPediatric-Type Follicular LymphomaDLBCL Germinal Center B-Cell TypeNodal Marginal Zone LymphomaLymphoplasmacytic LymphomaChronic Lymphocytic LeukemiaFollicular LymphomaPrimary Cutaneous Follicle Center LymphomaNCT05544019Schrödinger, Inc.98
Unknown
1 期
Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT03529526Alphamab (Australia) Co Pty Ltd.21
终止
1 期
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid TumorsAdvanced Malignant Solid TumorsNCT02045095Millennium Pharmaceuticals, Inc.29
终止
1 期
Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid TumorsNon-Hodgkin's Lymphoma,Solid TumorsNCT00100347PRAECIS Pharmaceuticals Inc.45
已完成
1 期
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard TherapyLiver MetastasesCholangiocarcinomaHepatocellular CarcinomaNCT04676633Sirnaomics5